# Tirzepatide

Canonical source: https://retacompare.com/encyclopedia/tirzepatide

Dual GIP / GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, slows gastric emptying, and improves adipocyte fatty-acid handling.

Reference facts

Also known asMounjaro, Zepbound, LY3298176CategoryGLP-1 & MetabolicMechanism of actionDual GIP / GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, slows gastric emptying, and improves adipocyte fatty-acid handling.TargetsGIPR, GLP-1RIndications under research or approvedType 2 Diabetes, Obesity, Obstructive Sleep Apnea (OSA)Regulatory status (reference entry)FDA-approved (Mounjaro 2022 for T2D; Zepbound 2023 for chronic weight management; OSA 2024)Half-life~120 hours (~5 days)SequenceYXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPSSequence notes39-residue dual GIP/GLP-1 agonist with Aib at positions 2 and 13 (X) and a C20 fatty diacid linker at Lys20.Molecular weight (Da)4814PDB accession7RTIOriginator / sponsorEli LillyFirst reported2018OriginDisclosed by Eli Lilly in 2018 as a unimolecular dual incretin.
    Primary References

SURPASS-2 — Tirzepatide vs Semaglutide in T2D, NEJM 2021

SURMOUNT-1 — Tirzepatide for obesity, NEJM 2022

FDA Mounjaro label


    Explore research articles about Tirzepatide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- SURPASS-2 — Tirzepatide vs Semaglutide in T2D, NEJM 2021: https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
- SURMOUNT-1 — Tirzepatide for obesity, NEJM 2022: https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
- FDA Mounjaro label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf